Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805
Year: 2022
Type: article
Abstract: BACKGROUND: E3805 (CHAARTED) is a phase 3 trial demonstrating improved survival for men with metastatic hormone-sensitive prostate cancer (mHSPC) randomized to treatment with docetaxel (D) and androgen-deprivation therapy (ADT) versus ADT alone. We assessed the association of baseline body mass index (BMI) and metformin exposure with quality of life (QOL) and prostate cancer outcomes including survival in patients enrolled in the CHAARTED study. METHODS: We performed a posthoc exploratory analysis of the CHAARTED trial of men with mHSPC randomized to treatment with ADT with or without D between 2006 and 2012. Cox proportional hazards models and Kruskal-Wallis test were used to evaluate the association between BMI with QOL and prostate cancer outcomes and between metformin exposure and survival. RESULTS: In 788 of 790 enrolled patients with prospectively recorded baseline BMI and metformin exposure status, lower BMI was not associated with survival, but was associated with high volume disease (p < 0.0001) and poorer baseline QOL on functional assessment of cancer therapy-prostate (p = 0.008). Only 68 patients had prevalent metformin exposure at baseline in the CHAARTED trial. Four groups were identified: ADT + D + metformin (n = 39); ADT + D (n = 357); ADT + metformin (n = 29); and ADT alone (n = 363). Baseline clinicopathologic characteristics were similar between groups. In this small exploratory multivariable analysis, metformin exposure was not associated with survival (hazard ratio: 1.15; 95% confidence interval: 0.81-1.63, p = 0.44). CONCLUSIONS: There was no link between baseline BMI and survival, but lower baseline BMI was associated with features of greater cancer burden and poorer QOL.
Source: The Prostate
DOI: 10.1002/pros.24369
Authors: Alicia K. Morgans, Yu‐Hui Chen, David F. Jarrard, Michael Carducci, Glenn Liu, Mario Eisenberger, Elizabeth R. Plimack, Alan Bryce, Jorge A. Garcia, Robert Dreicer, Nicholas J. Vogelzang, Joel Picus, Daniel Shevrin, Maha Hussain, Robert S. DiPaola, David Cella, Christopher J. Sweeney, The ECOG‐ACRIN E3805 Investigators
Institutions: Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Dana-Farber Cancer Institute, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Johns Hopkins University, Fox Chase Cancer Center, Temple University Health System, Mayo Clinic, Mayo Clinic in Arizona, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, University of Virginia Cancer Center, University of Virginia, Nevada Cancer Research Foundation, Comprehensive Cancer Centers of Nevada, Washington University in St. Louis, Cleveland Clinic, Endeavor Health, University of Kentucky, Harvard University, Dana-Farber/Harvard Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Eastern Cooperative Oncology Group, ECOG Statistical Office Data Management Grant, G1545560008, G1814228702, ECOG-ACRIN Network Group Operations Center, G1938688226, G1946161885, Participation in the Eastern Cooperative Oncology Group, G2398472636, G2679961467, G3053988604, G3100437649, G3475623468, G3519244048, G3521018462, G36541222, SWOG Network Group Operations Center of the NCTN, G3762168461, G3996959562, ECOG-ACRIN NCORP Research Base, G4701663385, G4874177819, Eastern Cooperative Oncology Group Studies, G5264753430, G557084418, NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care, Cancer and Leukemia Group B, ECOG-ACRIN Network Group Statistics and Data Management Center, G6944741171, Johns Hopkins University NCTN Lead Academic Site Program, Nevada Cancer Research foundation-Community Clinical Oncology Program, EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES, Eastern Cooperative Oncology Group Operations Office, Vanderbilt Network Lead Academic Participating Site for the NCTN, National Clinical Trials Network Research at the University of Wisconsin, Alliance for Clinical Trials in Oncology Operations Center
OpenAlex ID: W4280599443